Companies Attending VIVE Event 2025

Developer of patient engagement software designed to simplify digital payments and workflow for pharmacies. The company's platform offers features like secure messaging, intelligent engagement, frictionless payment, patient charts, and clinical engagement, enabling pharmacies to automate manual tasks.

DoseSpot is a Surescripts certified e-Prescribing platform specifically designed to integrate with electronic health record, electronic dental record, practice management and telehealth software. DoseSpot is certified to e-Prescribe controlled substances and has provided simple, affordable and integratable e-Prescribing solutions to healthcare IT companies since 2009. For more information, please visit http://www.DoseSpot.com

Doximity is a digital platform for medical professionals. The company’s network members include over 70% of U.S. physicians across all specialties and practice areas. Doximity provides its verified clinical membership with digital tools built for medicine, enabling them to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers, and conduct virtual patient visits. Doximity’s mission is to help doctors be more productive so they can provide better healthcare for their patients.

Developer of a mobile app for diabetes management. DiabeticU offers personalized meal and exercise planning, medication and blood sugar level tracking, and an AI-powered virtual assistant. The app is integrated with wearable devices and includes a community feature for users to connect with others living with diabetes.

Operator of a digital product engineering services firm intended to help companies drive innovation and achieve their digital growth agendas. The company offers web, mobile, native, hardware and embedded technologies using algorithmic routing, big data mining via artificial intelligence as well as rendering 3-D models from 2-D CAT scans, thereby enabling clients to differentiate their business and thereby giving them a competitive advantage.

Diasyst launches the first Medication Intelligence solution for chronic disease management, enabling healthcare providers to make timely, quick, safe, and effective treatment decisions. Diasyst collects, computerizes, and maintains an ever-expanding knowledge base of thousands of pages of clinical guidelines, drug labels, research studies, and best practices, backed by decades of research at Emory University and the VA. Diasyst delivers treatment recommendations to decision-makers using our proprietary AI, saving time, increasing revenue, and optimizing patient outcomes.

Operator of a healthcare technology platform intended to create personalized digestive health recommendations for people who suffer from Irritable Bowel Syndrome. The company's application captures high-resolution data on all relevant inputs/outputs of Irritable Bowel Syndrome, aggregates data across a large network of patients, and uses machine learning to personalize each user's path to improved health, enabling users to improve digestive health efficiently.

Developer of a patient-focused digital platform designed to transform dental care. The company's platform offers machine learning-ready data that produces actionable, targeted insights to help dental teams to improve and allows users to contribute to the values-based dental care pledge, enabling patients and dental professionals to measure and optimize patient experiences and outcomes, driving improved revenue by improving loyalty and trust.

Developer of AI-technology firm commercializing evidence-based solutions designed to modernize care for complex brain disease in early detection and care management. The company's platform offers an AI-enabled platform for delivering decision intelligence to support proactive care in Alzheimer's disease and related dementias (ADRD), and the software provides passive ADRD detection with performance accuracy for prediction horizons.

Digital Diagnostics, formerly IDx, is a pioneering AI diagnostics company founded with a mission to transform the quality, accessibility, equity, and affordability of healthcare worldwide through the application of technology in the medical diagnosis and treatment process. Founded by Michael Abramoff, MD, PhD, a fellowship-trained retina specialist, neuroscientist, and computer engineer, Digital Diagnostics developed a patented biomarker-based approach to build an autonomous AI platform that makes clinical decisions without human intervention, removing the diagnostic burden of common diseases from specialists. Digital Diagnostics is paving the way for autonomous AI diagnosis to become the new standard of care, helping to democratize healthcare and close care gaps to improve patient outcomes. By working closely with patient advocacy groups, federal regulators, and other quality of care and ethics-focused stakeholders, Digital Diagnostics is working with the healthcare system to enable the continued adoption of autonomous AI.